FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194565705> ?p ?o ?g. }

• W3194565705 endingPage "760" @default.
• W3194565705 startingPage "760" @default.
• W3194565705 abstract "Finerenone was recently approved by the US Food and Drug Administration for treatment of diabetic kidney disease (DKD). However, the commentary from Sridhar et al1Sridhar V.S. Liu H. Cherney D.Z.I. Finerenone - a new frontier in renin-angiotensin-aldosterone system inhibition in diabetic kidney disease.Am J Kidney Dis. 2021; 78: 309-311Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar on the FIDELIO trial2Bakris G.L. Agarwal R. Anker S.D. et al.Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.N Engl J Med. 2020; 383: 2219-2229Crossref PubMed Scopus (280) Google Scholar minimizes hyperkalemia and overstates the superiority of finerenone over other mineralocorticoid receptor antagonists (MRAs). The authors state that few patients discontinued finerenone owing to hyperkalemia (2.3% vs 0.9%). However, the enrollment criteria were crafted to minimize this, requiring a potassium level <4.8 mEq/L during screening and run-in, resulting in almost 60% exclusion.2Bakris G.L. Agarwal R. Anker S.D. et al.Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.N Engl J Med. 2020; 383: 2219-2229Crossref PubMed Scopus (280) Google Scholar Other clinically significant hyperkalemia outcomes are also higher (Table 1). It is likely that hyperkalemia will be more common in a real-world population of patients with chronic kidney disease (CKD), given the experience with spironolactone in heart failure.3Juurlink D.N. Mamdani M.M. Lee D.S. et al.Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.N Engl J Med. 2004; 351: 543-551Crossref PubMed Scopus (1371) Google ScholarTable 1Details About Hyperkalemia in the FIDELIO TrialCharacteristicaNumbers as reported based on the trial outcome definitions; see Bakris et al2 for details.FinerenonePlaceboPotassium binder use at baseline70 (2.5 %)66 (2.3 %)Potassium binder use through the trial307 (10.8%)184 (6.5%)Investigator-reported hyperkalemia516 (18.3 %)255 (9 %)Serious hyperkalemia44 (1.6 %)12 (0.4 %)Hospitalization owing to hyperkalemia40 (1.4 %)8 (0.3 %)Development of end-stage kidney diseasebPresented to contrast magnitude of small absolute benefit against the similar or higher absolute risk of hyperkalemia events.119 (4.2 %)139 (4.9 %)a Numbers as reported based on the trial outcome definitions; see Bakris et al2Bakris G.L. Agarwal R. Anker S.D. et al.Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.N Engl J Med. 2020; 383: 2219-2229Crossref PubMed Scopus (280) Google Scholar for details.b Presented to contrast magnitude of small absolute benefit against the similar or higher absolute risk of hyperkalemia events. Open table in a new tab Additionally, the claim that finerenone is superior to and safer than other MRAs reflects an absence of evidence rather than an evidence of absence of benefit. Steroidal MRAs reduce proteinuria and blood pressure in CKD,4Currie G. Taylor A.H.M. Fujita T. et al.Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.BMC Nephrol. 2016; 17: 127Crossref PubMed Scopus (73) Google Scholar and the larger and longer trials for kidney protection have just not been done. Only 1 trial directly compared finerenone and spironolactone in CKD patients,5Pitt B. Kober L. Ponikowski P. et al.Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.Eur Heart J. 2013; 34: 2453-2463Crossref PubMed Scopus (272) Google Scholar enrolling ~65 participants per arm and reporting a very modest difference (<0.1 mEq/L) in mean potassium concentration over 1 month of follow-up. We need clear guidance to navigate through the embarrassment of riches suddenly at our disposal for treatment of DKD. In order to fully understand the role of finerenone in this armamentarium, larger and adequately powered trials will help establish finerenone’s superiority to other MRAs. The authors declare that they have no relevant financial interests. Received July 5, 2021. Direct editorial input from an Associate Editor and a Deputy Editor. Accepted in revised form July 25, 2021. Finerenone—A New Frontier in Renin-Angiotensin-Aldosterone System Inhibition in Diabetic Kidney DiseaseAmerican Journal of Kidney DiseasesVol. 78Issue 2PreviewGlycemic control, blood pressure control, and single-agent renin-angiotensin-aldosterone system (RAAS) blockade were, until recently, the pillars of managing diabetic kidney disease (DKD). Although the introduction of sodium/glucose cotransporter 2 (SGLT2) inhibitors has further reduced DKD progression, patients continue to have significant residual risk, underlying the importance of identifying new therapies. In FIDELIO-DKD, Bakris et al1 demonstrate that the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (once daily 10-20 mg), on top of standard of care, is beneficial in DKD management. Full-Text PDF In Reply to ‘Finerenone: Fiddling With Hyperkalemia?’American Journal of Kidney DiseasesVol. 78Issue 5PreviewWe thank Waitzman et al1 for their comments. We agree that MRAs raise hyperkalemia risk and should be used cautiously to avoid subsequent higher rates of hyperkalemia.2 While there is evidence that nonsteroidal MRAs including finerenone increase potassium to a lesser extent than spironolactone,3 clinicians will need to exercise caution when using these therapies in patients with CKD. Full-Text PDF" @default.
• W3194565705 created "2021-08-30" @default.
• W3194565705 creator A5007769598 @default.
• W3194565705 creator A5013058267 @default.
• W3194565705 creator A5044179329 @default.
• W3194565705 date "2021-11-01" @default.
• W3194565705 modified "2023-09-23" @default.
• W3194565705 title "Finerenone: Fiddling With Hyperkalemia?" @default.
• W3194565705 cites W2111945961 @default.
• W3194565705 cites W2138612646 @default.
• W3194565705 cites W2510521632 @default.
• W3194565705 cites W3094429645 @default.
• W3194565705 cites W3138541724 @default.
• W3194565705 doi "https://doi.org/10.1053/j.ajkd.2021.07.006" @default.
• W3194565705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34400243" @default.
• W3194565705 hasPublicationYear "2021" @default.
• W3194565705 type Work @default.
• W3194565705 sameAs 3194565705 @default.
• W3194565705 citedByCount "2" @default.
• W3194565705 countsByYear W31945657052021 @default.
• W3194565705 countsByYear W31945657052022 @default.
• W3194565705 crossrefType "journal-article" @default.
• W3194565705 hasAuthorship W3194565705A5007769598 @default.
• W3194565705 hasAuthorship W3194565705A5013058267 @default.
• W3194565705 hasAuthorship W3194565705A5044179329 @default.
• W3194565705 hasBestOaLocation W31945657051 @default.
• W3194565705 hasConcept C126322002 @default.
• W3194565705 hasConcept C134018914 @default.
• W3194565705 hasConcept C159641895 @default.
• W3194565705 hasConcept C177713679 @default.
• W3194565705 hasConcept C189135053 @default.
• W3194565705 hasConcept C2776379505 @default.
• W3194565705 hasConcept C2777180221 @default.
• W3194565705 hasConcept C2778525890 @default.
• W3194565705 hasConcept C2778653478 @default.
• W3194565705 hasConcept C2780072264 @default.
• W3194565705 hasConcept C2780243291 @default.
• W3194565705 hasConcept C2908647359 @default.
• W3194565705 hasConcept C555293320 @default.
• W3194565705 hasConcept C71924100 @default.
• W3194565705 hasConcept C99454951 @default.
• W3194565705 hasConceptScore W3194565705C126322002 @default.
• W3194565705 hasConceptScore W3194565705C134018914 @default.
• W3194565705 hasConceptScore W3194565705C159641895 @default.
• W3194565705 hasConceptScore W3194565705C177713679 @default.
• W3194565705 hasConceptScore W3194565705C189135053 @default.
• W3194565705 hasConceptScore W3194565705C2776379505 @default.
• W3194565705 hasConceptScore W3194565705C2777180221 @default.
• W3194565705 hasConceptScore W3194565705C2778525890 @default.
• W3194565705 hasConceptScore W3194565705C2778653478 @default.
• W3194565705 hasConceptScore W3194565705C2780072264 @default.
• W3194565705 hasConceptScore W3194565705C2780243291 @default.
• W3194565705 hasConceptScore W3194565705C2908647359 @default.
• W3194565705 hasConceptScore W3194565705C555293320 @default.
• W3194565705 hasConceptScore W3194565705C71924100 @default.
• W3194565705 hasConceptScore W3194565705C99454951 @default.
• W3194565705 hasIssue "5" @default.
• W3194565705 hasLocation W31945657051 @default.
• W3194565705 hasLocation W31945657052 @default.
• W3194565705 hasOpenAccess W3194565705 @default.
• W3194565705 hasPrimaryLocation W31945657051 @default.
• W3194565705 hasRelatedWork W2009328678 @default.
• W3194565705 hasRelatedWork W2071416829 @default.
• W3194565705 hasRelatedWork W2168712739 @default.
• W3194565705 hasRelatedWork W2271304487 @default.
• W3194565705 hasRelatedWork W2981713925 @default.
• W3194565705 hasRelatedWork W3194565705 @default.
• W3194565705 hasRelatedWork W3201351742 @default.
• W3194565705 hasRelatedWork W3203785131 @default.
• W3194565705 hasRelatedWork W4293920968 @default.
• W3194565705 hasRelatedWork W4309922716 @default.
• W3194565705 hasVolume "78" @default.
• W3194565705 isParatext "false" @default.
• W3194565705 isRetracted "false" @default.
• W3194565705 magId "3194565705" @default.
• W3194565705 workType "article" @default.